CME in Minutes: Education in Rheumatology, Immunology, & Infectious Diseases

CME in Minutes: Education in Rheumatology, Immunology, & Infectious Diseases

Download on the App Store

CME in Minutes: Education in Rheumatology, Immunology, & Infectious Diseases episodes

  • Peter Lio, MD - Generative AI: Benefits for Your Practice, for Your Patients
    Please visit answersincme.com/XGU860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert dermatologist—who is also an early adopter of generative artificial intelligence (AI)—discusses capabilities and potential applications of generative AI in healthcare, both for clinicians and patients. Upon completion of this activity, participants should be better able to: Describe how generative AI is impacting the practice of medicine both from the clinicians’ and patients’ perspectives; and Assess the potential benefits and risks of using generative AI in medical practice.
    13 min
  • Martin C. Mahoney, MD, PhD - Reducing the Burden of HPV-Related Cancers: Strategies for Improving HPV Vaccine Uptake in Males
    Please visit answersincme.com/XXZ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses human papillomavirus (HPV) vaccination in males to reduce the burden of HPV-related cancers. Upon completion of this activity, participants should be better able to: Recognize the rationale for vaccination against HPV infection in the male population; Describe the clinical evidence for the guideline-recommended HPV vaccines; and Outline strategies to enhance acceptance of HPV vaccination among the male population.
    16 min
  • Juliana M. Kling, MD, MPH - Improving Inclusive Care: Enhancing HPV Vaccine Uptake Among LGBTQ+ Individuals
    Please visit answersincme.com/GHX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in women’s health discusses improving human papillomavirus (HPV) vaccination uptake among lesbian, gay, bisexual, transgender, and queer (LGBTQ+) individuals. Upon completion of this activity, participants should be better able to: Identify the clinical impact of low uptake of HPV vaccination among LGBTQ+ individuals; Review the clinical profiles and suggested administration of guideline-recommended HPV vaccines; and Outline patient-centered strategies to enhance acceptance of HPV vaccination among LGBTQ+ individuals.
    16 min
  • John N. Allan, MD - Enhancing Patient Outcomes in Relapsed/Refractory Follicular Lymphoma: Recognizing the Role of Novel Bispecific Antibody–Based Therapies
    Please visit answersincme.com/NRW860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematology-oncology discusses the optimization of care for patients with relapsed/refractory follicular lymphoma (R/R FL) and treatment with bispecific antibodies (BsAbs). Upon completion of this activity, participants should be better able to: Recognize the clinical rationale for using BsAbs in patients with R/R FL; Review the clinical profiles of novel anti-CD20 × CD3 BsAbs for R/R FL; and Describe patient-centered strategies to manage BsAb-associated adverse events in R/R FL.
    15 min
  • Jonathan Barker, BSc, MB, BS, MD, FRCP - Novel Approved and Emerging IL-36 Receptor Inhibitors for the Treatment of GPP
    Please visit answersincme.com/PJR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, Jonathan Barker, BSc, MB, BS, MD, FRCP, an expert in dermatology, discusses unmet therapeutic needs in the treatment of generalized pustular psoriasis (GPP). Upon completion of this activity, participants should be better able to: Recognize the burden of generalized pustular psoriasis (GPP), including unmet therapeutic needs; Explain the rationale for the use of IL-36 receptor inhibitors in treating GPP; and Describe the clinical profiles of novel approved and emerging IL-36 receptor inhibitors for the treatment of GPP.
    15 min
  • Nicola A. Hanania, MD, MS - Enough: Targeting Eosinophilic Pathways With Biologics in Chronic Obstructive Pulmonary Disease
    Please visit answersincme.com/TXC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonology discusses the unmet therapeutic needs in patients with chronic obstructive pulmonary disease (COPD) and the rationale for targeting Type 2 inflammation. Upon completion of this activity, participants should be better able to: Recognize the unmet therapeutic needs in patients with COPD; Identify patients with COPD who are at high risk of exacerbations despite receiving standard therapies; and Recognize the rationale for targeting Type 2 inflammation for the treatment of COPD.
    16 min
  • Michael Wechsler, MD - On the Case to Improve Outcomes in Uncontrolled Asthma: Best Practices to Enhance Clinical Care
    Please visit answersincme.com/NQF860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonology discusses current guideline-supported best practices in the management of moderate to severe asthma. Upon completion of this activity, participants should be better able to: Review current guideline recommendations regarding the use of oral corticosteroids (OCS) in patients with moderate to severe asthma; Recognize the latest clinical data concerning the use of biologics in patients with moderate to severe asthma on oral corticosteroids; and Outline patient-centered, practical strategies to enhance the long-term care of patients with moderate to severe asthma.
    17 min
  • Jennifer Hill, MD - Breathing New Air Into Improved Outcomes: Strategies to Optimize Care in Patients With Uncontrolled Asthma
    Please visit answersincme.com/RYY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in allergy/immunology discusses treatment intensification for adult and pediatric patients with uncontrolled asthma. Upon completion of this activity, participants should be better able to: Review current guideline recommendations regarding the use of oral corticosteroids in patients with moderate to severe asthma; Recognize the latest clinical data concerning the use of biologics in patients with moderate to severe asthma on oral corticosteroids; and Outline patient-centered, practical strategies to enhance the long-term care of patients with moderate to severe asthma.
    16 min
  • Shawn Kwatra, MD - Itching for Relief: Exploring the Role of Novel Biologics in Prurigo Nodularis
    Please visit answersincme.com/SRG860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in dermatology discuss the diagnosis and treatment of prurigo nodularis. Upon completion of this activity, participants should be better able to: Recognize the need for treatment intensification in patients with prurigo nodularis (PN), including patients of color, using novel biologic therapies; Review the clinical profiles of novel biologic therapies for PN; and Outline clinical factors that may facilitate the optimal use of biologic therapies in patients with PN.
    17 min
  • Joshua Richter, MD / Saad Z. Usmani, MD, MBA, FACP - Optimizing Patient Outcomes in Relapsed/Refractory Multiple Myeloma: The Role of Novel BCMA-Targeted Bispecific Antibodies
    Please visit answersincme.com/GQB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in hematology-oncology discuss B-cell maturation antigen (BCMA)–targeted therapies in the treatment of relapsed/refractory multiple myeloma. Upon completion of this activity, participants should be better able to: Identify where BCMA-targeted therapies fit into the current treatment paradigm of RRMM; Describe the clinical profiles of new and emerging BCMA-targeted bispecific antibodies in heavily treated RRMM; and Outline strategies to optimally incorporate novel BCMA-targeted bispecific antibodies into the treatment paradigm of RRMM.
    17 min

About CME in Minutes: Education in Rheumatology, Immunology, & Infectious Diseases

From the publisher's feed

Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Rheumatology, Immunology, and Infectious Diseases by Answers in CME. Benefit from…

More shows like CME in Minutes: Education in Rheumatology, Immunology, & Infectious Diseases

Rheumnow Podcast by Dr. Cush

Rheumnow Podcast

125 Listeners

Healio Rheuminations by Adam J. Brown, MD

Healio Rheuminations

120 Listeners

Harrison's PodClass: Internal Medicine Cases and Board Prep by AccessMedicine

Harrison's PodClass: Internal Medicine Cases and Board Prep

369 Listeners

Cardionerds: A Cardiology Podcast by CardioNerds

Cardionerds: A Cardiology Podcast

430 Listeners

CME in Minutes: Education in Dermatology by Answers in CME

CME in Minutes: Education in Dermatology

3 Listeners

CME in Minutes: Education in Oncology & Hematology by Answers in CME

CME in Minutes: Education in Oncology & Hematology

7 Listeners

CME in Minutes: Education in Ophthalmology by Answers in CME

CME in Minutes: Education in Ophthalmology

2 Listeners

CME in Minutes: Education in Cardiology & Pulmonology by Answers in CME

CME in Minutes: Education in Cardiology & Pulmonology

3 Listeners

CME in Minutes: Education in Primary Care by Answers in CME

CME in Minutes: Education in Primary Care

7 Listeners